Connect with us
Information

WORLD EDITION
Australia
North America
World

Investing News NetworkYour trusted source for investing success

WORLD EDITION
North America
Australia
World
My INN

Private Placements

Reports & Guides
- Market Outlook Reports
- Investing Guides
Button

Precious Metals
Battery Metals
Base Metals
Energy
Critical Metals

nasdaq:sbtx

POPULAR ARTICLES

ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®

Life Science Investing

ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®

neffy® Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions

Life Science Investing

neffy® Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions

Real-World Evidence Supports Clinical Effectiveness of neffy® in Patients Experiencing Anaphylaxis

Life Science Investing

Real-World Evidence Supports Clinical Effectiveness of neffy® in Patients Experiencing Anaphylaxis

LATEST ARTICLES

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

Life Science Investing

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy®

Life Science Investing

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy®

ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results

life science investing

ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results

ARS Pharmaceuticals Submits Response for neffy® Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand

life science investing

ARS Pharmaceuticals Submits Response for neffy® Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand

Silverback Therapeutics Inc.

Silverback Therapeutics Inc.

Biopharma Hopes to Keep Generalist Investor Attention in 2021

biotech investing

Biopharma Hopes to Keep Generalist Investor Attention in 2021

Latest News

Canadian Investment Regulatory Organization Trade Resumption - ANK

Angkor Resources Receives Preliminary Feedback on the First Basin of the Seismic Program with Enercam's Oil & Gas Block VIII, Cambodia

LaFleur Minerals Provides Update on PEA for the Restart of Beacon Gold Mill Sourcing Material from Its Swanson Gold Deposit, Val d'Or, Québec

Homerun Resources Inc. Financing Updates

Finlay Minerals Announces Non-Brokered Private Placement of Flow-Through and Non-Flow-Through Units

Outlook Reports

Precious Metals
- Gold
- Silver
Battery Metals
Agriculture

Base Metals
Critical Metals
- Rare Earths
Energy
- Uranium
- Oil and Gas

- Crypto
- Cleantech

- Biotech
- Cannabis

- Pharmaceuticals

Featured Stocks

Mount Hope Mining

MHM:AU

International Graphite

IG6:AU

Skyharbour Resources

SYH:CA

African Discovery Group

AFDG

Walker Lane Resources

WLR:CC

Rua Gold

RUA:CC

More featured stocks

Browse Companies

Precious Metals
Battery Metals
Energy

Base Metals
Critical Metals

MARKETS

COMMODITIES

CURRENCIES